<DOC>
	<DOCNO>NCT02882009</DOCNO>
	<brief_summary>The purpose randomize , open-label , parallel-group , placebo-controlled study ass pain follow subcutaneous ( SC ) administration gantenerumab high-concentration liquid formulation ( HCLF ) different injection speed . The total duration study healthy participant approximately 21 week .</brief_summary>
	<brief_title>A Study Assess Impact Speed Site Subcutaneous Injection Pain , Tolerability , Safety , Pharmacokinetics Gantenerumab Healthy Participants</brief_title>
	<detailed_description />
	<mesh_term>Antibodies , Monoclonal</mesh_term>
	<criteria>Healthy male female participant ( healthy status define absence evidence active chronic disease follow detailed medical surgical history , complete physical examination include vital sign , 12lead electrocardiogram , hematology , blood chemistry , coagulation , serology , urinalysis ) Body mass index 18.0 30.0 kilogram per meter square ( kg/m^2 ) , inclusive Female participant childbearing potential must commit use two acceptable form contraception study least 6 month followup visit History clinically significant gastrointestinal , renal , hepatic , bronchopulmonary , neurological , psychiatric , cardiovascular , endocrinological , hematological allergic disease , metabolic disorder , cancer , cirrhosis History suspicion drug abuse alcohol addiction Smokers smoke 10 cigarette per day equivalent amount tobacco determine history Pregnant lactate woman Positive result hepatitis B virus ( HBV ) , hepatitis C virus ( HCV ) , Human immunodeficiency virus ( HIV ) 1 2 Any familial history early onset Alzheimer 's disease Prior administration gantenerumab Participation investigational drug medicinal product medical device study within 90 day dose within seven time elimination halflife , whichever longer Any abnormal skin condition potentially obscure tattoo , pigmentation , lesion area intend SC injection</criteria>
	<gender>All</gender>
	<minimum_age>40 Years</minimum_age>
	<maximum_age>80 Years</maximum_age>
	<verification_date>August 2016</verification_date>
</DOC>